Comparison of Two Different Approaches in the Fascia Iliaca Compartment Block in Femoral Fracture Surgery

NCT ID: NCT05172869

Last Updated: 2022-12-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

68 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-02-09

Study Completion Date

2022-11-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Fascia Iliaca Compartment Block (FICB) is a popular regional anaesthetic technique for surgical procedures involving the hip joint and femur. The FICB may be thought of as an anterior approach to the lumbar plexus where local anaesthetic is injected proximally beneath the fascia iliaca, with the aim of blocking the femoral nerve ,obturator nerve and lateral cutaneous nerve of thigh simultaneously.

In addition to providing effective analgesia, peripheral nerve blocks are increasingly preferred especially in frail patient groups such as the geriatric population which femoral fractures are the most common, because of their advantages such as avoiding the complications of neuraxial anesthesia and the side effects of opioids.

FICB can be applied with ultrasound-guided suprainguinal or infrainguinal approaches. Studies on the superiority of the two methods used in clinical practice are limited. In this study, it is aimed to compare the suprainguinal (Group S) and infrainguinal (Group I) approaches of FICB applied in the preoperative period in femoral fractures in which spinal anesthesia method was chosen. These two methods will be compared in terms of postoperative pain scores (11-point numeric scale), morphine consumption (by intravenous patient controlled analgesia for postoperative 24 hours) and possible side effects-complications.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

After ethical committee approval, at least 68 patients who will undergo surgery for femoral fracture will be included in the study. Our study was planned as prospective, randomized, double-blind.

At least 68 patients of both sexes, 18 years of age and older, American Society of Anesthesiologists Score-1,2,3 ( ASA 1,2,3) who will undergo surgery for femoral fracture will be included.

Patients who will undergo surgery will be divided into two randomized groups, each containing 34 patients, in the preoperative unit with a randomization program, as the group in which FICB was applied with the suprainguinal approach (Group S) and the group in which FICB was applied with the infrainguinal approach (Group I).

Routine monitoring \[electrocardiogram (ECG), noninNRSive blood pressure, peripheral oxygen saturation (SpO2) measured by pulse oximetry\] will be performed for both groups, and heart rate (beats/minute), blood pressure (mmHg), SpO2 (%) will be recorded. Pain intensity, as measured by the 11-Point Numerical Rating Scale (NRS) for pain (0: no pain, 10: worst pain imaginable) will be recorded. All patients in both groups will be administered a mixture of 200mg 2% lidocaine and 0.25% 75mg bupivacaine, with a total volume of 40 ml, with an 80 mm peripheral block needle, accompanied by ultrasonography (US). To avoid toxic doses of local anesthetics, patients with a body weight of less than 50 kg will not be included in the study.

Patients in both groups will undergo sensory examination every 5 minutes for 30 minutes after FICB is performed (sensory: 0, hypoesthesia: 1, no sensation: 2). Sensory examination scoring will be performed and recorded separately for femoral nerve, lateral femoral cutaneous nerve and obturator nerve derivations. Patients with NRS 0-4 and a total sensory scale score for three leads 3 out of 6 will be considered suitable for positioning spinal anesthesia. Among these patients, patients with a sensory scale of 5 and 6 points will be considered as complete block, and their full block duration will be recorded.

The patient will be placed on the operating table in the lateral decubitus position with the fractured side down, and the dynamic NRS (pain score during the lateral decubitus positioning movement with the patient's fractured side down) and static NRS value will be recorded to determine the pain caused by this position. In patients with unsuccessful sensory block application (sensory scale total is 2 or less out of 6, NRS is 5 and above), 0.03 mg/kg midazolam and 1 μg/kg fentanyl will be administered as an intravenous (iv) bolus, and this information will be recorded.

The comfort of the anesthesiologist performing the spinal anesthesia will be recorded (Poor: 0, fair: 1, good: 2, very good: 3).

The heart rate, blood pressure, SpO2 values and pain scores of the patients in both groups will be recorded as static NRS (pain score at rest) before FICB, static NRS and dynamic NRS during position for spinal anesthesia after FICB, and static NRS at the 5th minute after spinal anesthesia.

Heart rate, blood pressure and SpO2 values will be recorded every 15 minutes throughout the operation.

At the end of the operation, the patients will be followed in Postanesthesia Caring Unit (PACU) for the first 24 hours postoperatively. At the end of 24 hours, patients with a Modified Aldrete Score of 9 and above will be transferred to the ward and the follow-up will be terminated.

All patients in both groups will receive intravenous patient-controlled analgesia (PCA) prepared with morphine at the end of the operation. In the PCA device, only the bolus dose program will be selected and it will be prepared with morphine at a concentration of 0.2 mg/ml (30 mg of morphine will be supplemented with 0.09% isotonic saline, so that the total volume will be 150 ml). It will be adjusted as the bolus dose 1 mg, the lock time 20 minutes, the 4-hour limit 8 mg. Basal infusion will not be administered, and when the patient has pain with a NRS score of 5 or more in the postoperative period, bolus administration will be performed with the patient button of the PCA device and each bolus will be recorded by the device. The use of the PCA device will be explained in detail to the patients. Patients whose have pain of NRS 5 and above, but cannot cooperate to press the bolus button (patients who show partial cooperation due to dementia, etc.) a bolus dose will be administered by PACU nurse or anesthesiologist.

Patients will be followed for the first 24 hours with vitals, postoperative pain scores (NRS) and possible opioid side effects related to IV morphine PCA administration. Static and dynamic NRS scores of the patients at 0, 2, 8, 16 and 24 hours postoperatively, at which hour in the postoperative period the first analgesic requirement (time to administer the first bolus dose with the PCA device due to NRS 5 and above), the total amount of opioid consumed during the 24 hours (mg morphine /24 hours) and any side effects (itching, nausea, vomiting, urinary retention, delirium, somnolence, respiratory distress-hypoxia, etc.) will be recorded.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Femoral Fractures Postoperative Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Patients who will undergo surgery will be divided into two randomized groups, each containing 34 patients, in the preoperative unit with a randomization program, as the group in which FICB was applied with the suprainguinal approach (Group S) and the group in which FICB was applied with the infrainguinal approach (Group I).

FICB can be applied with ultrasound-guided suprainguinal or infrainguinal approaches. Studies on the superiority of the two methods used in clinical practice are limited. In this study, it is aimed to compare the suprainguinal (Group S) and infrainguinal (Group I) approaches of FICB applied in the preoperative period in femoral fractures. These two methods will be compared in terms of postoperative pain scores (11-point numeric scale), morphine consumption (by intravenous patient controlled analgesia for postoperative 24 hours) and possible side effects-complications.
Primary Study Purpose

OTHER

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group S: Suprainguinal Performed FICB

Suprainguinal Performed FICB

Group Type ACTIVE_COMPARATOR

Suprainguinal Performed FICB

Intervention Type PROCEDURE

Linear ultrasound probe places above inguinal ligament sagittally, close to the femoral crease and superior-lateral to the femoral artery. It is aimed to spreading local anesthetics under the fascia iliaca medial-laterally

Group I: Infrainguinal Performed FICB

Infrainguinal Performed FICB

Group Type ACTIVE_COMPARATOR

Infrainguinal Performed FICB

Intervention Type PROCEDURE

Linear ultrasound probe places below inguinal ligament transversally, close to the femoral crease and lateral to the femoral artery. It is aimed to spreading local anesthetics under the fascia iliaca medial-laterally

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Suprainguinal Performed FICB

Linear ultrasound probe places above inguinal ligament sagittally, close to the femoral crease and superior-lateral to the femoral artery. It is aimed to spreading local anesthetics under the fascia iliaca medial-laterally

Intervention Type PROCEDURE

Infrainguinal Performed FICB

Linear ultrasound probe places below inguinal ligament transversally, close to the femoral crease and lateral to the femoral artery. It is aimed to spreading local anesthetics under the fascia iliaca medial-laterally

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Undergo femoral fracture surgery
* ASA 1-2-3
* 18 years and older
* Accepting preoperative fascia iliaca compartment block application

Exclusion Criteria

* Patients younger than 18 years
* Patients with an ASA score of 4 and greater than 4
* Patients who are unable to read, understand and sign the consent form
* Patients who do not want to sign the consent form
* Patients deemed unsuitable by the investigator
* Patients with body weight less than 50 kg
* Patients with hypersensitivity to local anesthetics
* Patients with known neuropsychiatric disease
* Patients with coagulopathic disease or anticoagulant drug use that interferes with the application of neuraxial anesthesia or peripheral nerve blockade
* Patients with infection or active skin lesion at the application site of neuraxial anesthesia or peripheral nerve blockade
* Patients who need to be switched to general anesthesia due to spinal anesthesia insufficiency or complications before the operation is completed
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ankara City Hospital Bilkent

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Damla kocak

Research Assistant

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ayşe Lafçı

Role: PRINCIPAL_INVESTIGATOR

Ankara City Hospital Bilkent

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ankara City Hospital

Ankara, , Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Ankara City Hospital

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.